1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Hu, J. Asbury, T. Cross, T.A. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biophys.J. BIOJAU 0030 0006-3495 92 4335 4343 10.1529/biophysj.106.090183 17384070 Backbone structure of the amantadine-blocked trans-membrane domain m2 proton channel from influenza a virus. 2007 10.2210/pdb2h95/pdb pdb_00002h95 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 1958.496 Matrix protein 2 TRANSMEMBRANE DOMAIN (RESIDUES 26-43) 4 syn polymer no no LVVAASIIGILHLILWIL LVVAASIIGILHLILWIL A,B,C,D polypeptide(L) n n n n n n n n n n n n n n n n n n database_2 pdbx_nmr_spectrometer pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations 1 0 2007-04-24 1 1 2008-05-01 1 2 2011-07-13 1 3 2022-03-09 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_spectrometer.model RCSB Y RCSB 2006-06-08 REL REL THE PEPTIDE WAS SYNTHESIZED USING SOLID PHASE PEPTIDE SYNTHESIS. THIS SEQUENCE OCCURS NATURALLY IN THE INFLUENZA A VIRUS (UDORN/72). sample structures with the lowest energy 72 1 solid-State NMR PISEMA 8.8 AMBIENT 308 K REFINEMENT WAS CARRIED OUT IN VACUO ON INITIAL MONOMER COORDINATES CONSISTING OF TWO ALPHA-HELICAL FRAGMENTS (3.6 RESIDUES PER TURN) HAVING TILT AND ROTATIONAL ORIENTATIONS WITH RESPECT TO THE BILAYER DERIVED FROM PISEMA DIPOLAR WAVE ANALYSIS. ENERGY MINIMIZATION USED A GLOBAL PENALTY FUNCTION INCORPORATING ORIENTATIONAL RESTRAINTS, HYDROGEN BONDING AND THE CHARMM EMPIRICAL FUNCTION. THE ORIENTATIONAL RESTRAINTS IMPOSED ON THE STRUCTURE DURING REFINEMENT ARE 16 15N CHEMICAL SHIFTS AND 16 15N-1H DIPOLAR COUPLINGS FROM PISEMA EXPERIMENTS. A SYMMETRIC, TETRAMERIC BUNDLE MODEL OF M2-TMD WAS CONSTRUCTED BY A SERIES OF RIGID-BODY TRANSFORMATIONS OF THE REFINED M2-TMD MONOMER. THE RESULTING HOMO-TETRAMER IS THE LOWEST FREE ENERGY CONFORMER BASED ON ROTATIONAL CONFORMATIONAL SEARCH. NOTE THAT THE HIS37 AND TRP41 SIDECHAIN POSITIONS ARE CONSISTENT WITH MEASURED ORIENTATIONAL CONSTRAINTS. THE ROTAMERIC STATES OF OTHER RESIDUES ARE TAKEN FROM A BACKBONE DEPENDENT SIDECHAIN ROTAMER LIBRARY (SCRWL). ENERGY MINIMIZATION WITH ORIENTATIONAL CONSTRAINTS 1 lowest energy M2-TMD (~120 mg) and DMPC (~75 mg) were first co-dissolved in 10 ml TFE, followed by the removal of the solvent under vacuum. The peptide/lipid mixture was rehydrated and sonicated to make liposomes in a citrate-borate-phosphate (CBP) buffer (pH 8.8) with 1 mM EDTA and 10 mM amantadine at 310 K. The liposomes were pelleted by ultracentrifugation . Then the pellet was spread on glass slides and dehydrated in a 75% humidity chamber. The dehydrated slides were rehydrated with 1.5 microl liter CBP buffer per slide followed by being stacked into a glass tube and incubated at 316 K for 24 hours in 96% relative humidity. Finally, the glass tube was sealed at both ends with epoxy and two glasscaps. oriented peptide/lipid bilayer of M2_TMD and DMPC Schwieters, Kuszewski, Tjandra, Clore refinement XPLOR-NIH 2.9.9 400 Bruker AVANCE LEU 26 n 1 LEU 26 A VAL 27 n 2 VAL 27 A VAL 28 n 3 VAL 28 A ALA 29 n 4 ALA 29 A ALA 30 n 5 ALA 30 A SER 31 n 6 SER 31 A ILE 32 n 7 ILE 32 A ILE 33 n 8 ILE 33 A GLY 34 n 9 GLY 34 A ILE 35 n 10 ILE 35 A LEU 36 n 11 LEU 36 A HIS 37 n 12 HIS 37 A LEU 38 n 13 LEU 38 A ILE 39 n 14 ILE 39 A LEU 40 n 15 LEU 40 A TRP 41 n 16 TRP 41 A ILE 42 n 17 ILE 42 A LEU 43 n 18 LEU 43 A LEU 26 n 1 LEU 26 B VAL 27 n 2 VAL 27 B VAL 28 n 3 VAL 28 B ALA 29 n 4 ALA 29 B ALA 30 n 5 ALA 30 B SER 31 n 6 SER 31 B ILE 32 n 7 ILE 32 B ILE 33 n 8 ILE 33 B GLY 34 n 9 GLY 34 B ILE 35 n 10 ILE 35 B LEU 36 n 11 LEU 36 B HIS 37 n 12 HIS 37 B LEU 38 n 13 LEU 38 B ILE 39 n 14 ILE 39 B LEU 40 n 15 LEU 40 B TRP 41 n 16 TRP 41 B ILE 42 n 17 ILE 42 B LEU 43 n 18 LEU 43 B LEU 26 n 1 LEU 26 C VAL 27 n 2 VAL 27 C VAL 28 n 3 VAL 28 C ALA 29 n 4 ALA 29 C ALA 30 n 5 ALA 30 C SER 31 n 6 SER 31 C ILE 32 n 7 ILE 32 C ILE 33 n 8 ILE 33 C GLY 34 n 9 GLY 34 C ILE 35 n 10 ILE 35 C LEU 36 n 11 LEU 36 C HIS 37 n 12 HIS 37 C LEU 38 n 13 LEU 38 C ILE 39 n 14 ILE 39 C LEU 40 n 15 LEU 40 C TRP 41 n 16 TRP 41 C ILE 42 n 17 ILE 42 C LEU 43 n 18 LEU 43 C LEU 26 n 1 LEU 26 D VAL 27 n 2 VAL 27 D VAL 28 n 3 VAL 28 D ALA 29 n 4 ALA 29 D ALA 30 n 5 ALA 30 D SER 31 n 6 SER 31 D ILE 32 n 7 ILE 32 D ILE 33 n 8 ILE 33 D GLY 34 n 9 GLY 34 D ILE 35 n 10 ILE 35 D LEU 36 n 11 LEU 36 D HIS 37 n 12 HIS 37 D LEU 38 n 13 LEU 38 D ILE 39 n 14 ILE 39 D LEU 40 n 15 LEU 40 D TRP 41 n 16 TRP 41 D ILE 42 n 17 ILE 42 D LEU 43 n 18 LEU 43 D author_defined_assembly 4 tetrameric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 Structure of the Amantadine-Blocked Influenza A M2 Proton Channel Trans-membrane Domain by Solid-state NMR spectroscopy 1 N N 1 N N 1 N N 1 N N A LEU 26 A LEU 1 HELX_P A LEU 43 A LEU 18 1 1 18 B LEU 26 B LEU 1 HELX_P B LEU 43 B LEU 18 1 2 18 C LEU 26 C LEU 1 HELX_P C LEU 43 C LEU 18 1 3 18 D LEU 26 D LEU 1 HELX_P D LEU 43 D LEU 18 1 4 18 MEMBRANE PROTEIN ALPHA HELIX, PROTEIN-LIGAND, MEMBRANE PROTEIN M2_IAUSS UNP 1 26 P35938 LVVAASIIGILHLILWIL 26 43 2H95 26 43 P35938 A 1 1 18 26 43 2H95 26 43 P35938 B 1 1 18 26 43 2H95 26 43 P35938 C 1 1 18 26 43 2H95 26 43 P35938 D 1 1 18 1 P 1